CL2016000187A1 - Sales de derivados de 2-amino-1-hidroxietil-8-hidroxiquinolin-2(1h)-ona que tienen actividad antagonista de receptores muscarínicos así como actividad agonista del receptor b2 adrenérgico. - Google Patents

Sales de derivados de 2-amino-1-hidroxietil-8-hidroxiquinolin-2(1h)-ona que tienen actividad antagonista de receptores muscarínicos así como actividad agonista del receptor b2 adrenérgico.

Info

Publication number
CL2016000187A1
CL2016000187A1 CL2016000187A CL2016000187A CL2016000187A1 CL 2016000187 A1 CL2016000187 A1 CL 2016000187A1 CL 2016000187 A CL2016000187 A CL 2016000187A CL 2016000187 A CL2016000187 A CL 2016000187A CL 2016000187 A1 CL2016000187 A1 CL 2016000187A1
Authority
CL
Chile
Prior art keywords
hydroxyquinolin
hydroxyethyl
amino
derivatives
salts
Prior art date
Application number
CL2016000187A
Other languages
English (en)
Inventor
Duran Carlos Puig
Carrera Francesc Carrera
Jane Montserrat Julia
Quiñones Maria Prat
Andres Juan Antonio Perez
Loranzo Francesca Pajuelo
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48917474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016000187(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of CL2016000187A1 publication Critical patent/CL2016000187A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SAL DE ADICION CRISTALINA FARMACEUTICAMENTE ACEPTABLE DE I) UN DERIVADO DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA Y II) UN ACIDO DICARBOXILICO; COMPOSICION FARMACEUTICA; COMBINACION FARMACEUTICA; USO EN EL TRATAMIENTO DE ASMA Y EPOC.
CL2016000187A 2013-07-25 2016-01-25 Sales de derivados de 2-amino-1-hidroxietil-8-hidroxiquinolin-2(1h)-ona que tienen actividad antagonista de receptores muscarínicos así como actividad agonista del receptor b2 adrenérgico. CL2016000187A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13382304 2013-07-25

Publications (1)

Publication Number Publication Date
CL2016000187A1 true CL2016000187A1 (es) 2016-08-05

Family

ID=48917474

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000187A CL2016000187A1 (es) 2013-07-25 2016-01-25 Sales de derivados de 2-amino-1-hidroxietil-8-hidroxiquinolin-2(1h)-ona que tienen actividad antagonista de receptores muscarínicos así como actividad agonista del receptor b2 adrenérgico.

Country Status (36)

Country Link
US (1) US9579316B2 (es)
EP (1) EP3024489B1 (es)
JP (1) JP6374962B2 (es)
KR (1) KR102338155B1 (es)
CN (2) CN112321579A (es)
AR (1) AR097079A1 (es)
AU (1) AU2014295028B2 (es)
BR (1) BR112016001295B1 (es)
CA (1) CA2917596C (es)
CL (1) CL2016000187A1 (es)
CR (1) CR20160043A (es)
CY (1) CY1122920T1 (es)
DK (1) DK3024489T3 (es)
DO (1) DOP2016000011A (es)
EA (1) EA035436B1 (es)
ES (1) ES2788627T3 (es)
HR (1) HRP20200670T1 (es)
HU (1) HUE049441T2 (es)
IL (1) IL243173B (es)
LT (1) LT3024489T (es)
MX (1) MX360837B (es)
MY (1) MY184681A (es)
NI (1) NI201600012A (es)
NZ (1) NZ715128A (es)
PE (1) PE20160173A1 (es)
PH (1) PH12016500125A1 (es)
PL (1) PL3024489T3 (es)
PT (1) PT3024489T (es)
RS (1) RS60185B1 (es)
SG (1) SG11201510682YA (es)
SI (1) SI3024489T1 (es)
SM (1) SMT202000185T1 (es)
TW (1) TWI641373B (es)
UY (1) UY35678A (es)
WO (1) WO2015011244A1 (es)
ZA (1) ZA201509203B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
AU2013360866A1 (en) 2012-12-18 2015-07-02 Almirall, S.A. New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activity
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
CN105473133A (zh) 2013-04-30 2016-04-06 欧缇托匹克公司 干粉制剂及使用方法
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
CN107074833B (zh) * 2015-07-21 2021-05-25 四川海思科制药有限公司 具有β2受体激动及M3受体拮抗活性的苯并环衍生物及其在医药上的用途
CN106554350B (zh) * 2015-09-29 2019-12-20 四川海思科制药有限公司 具有β2激动活性的苯并杂环衍生物及其制法和应用
TW201835041A (zh) * 2017-02-17 2018-10-01 印度商托仁特生技有限公司 具β-腎上腺素促效劑及抗蕈毒活性化合物
EP3684338A4 (en) 2017-09-22 2021-06-23 Otitopic Inc. DRY POWDER COMPOSITIONS WITH MAGNESIUM STEARATE
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
WO2020244452A1 (zh) * 2019-06-06 2020-12-10 中国医药研究开发中心有限公司 具有β 2受体激动及M受体拮抗活性的杂环衍生物及其医药用途
IL301544A (en) * 2020-09-28 2023-05-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd Tricyclic substances and pharmaceutical preparations containing them
CN119053593A (zh) * 2022-03-25 2024-11-29 正大天晴药业集团股份有限公司 稠合三并环衍生物或其可药用盐的结晶

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1212742B (it) 1983-05-17 1989-11-30 Dompe Farmaceutici Spa Derivati dibenzo [1,4]diazepinonici pirido [1,4] benzodiazepinonici,pirido [1,5] benzodiazepinonici e loro attivita' farmacologica
DE3370320D1 (en) 1983-09-26 1987-04-23 Magis Farmaceutici Aminocyclohexanol derivatives having an expectorant activity, process for their preparation and pharmaceutical compositions containing them
EP1078629A3 (en) 1989-09-07 2001-05-23 Glaxo Group Limited Use of Salmeterol and salts for the treatment of inflammation and allergy
GB9020051D0 (en) 1990-09-13 1990-10-24 Pfizer Ltd Muscarinic receptor antagonists
WO1998009632A1 (en) 1996-09-06 1998-03-12 Merck & Co., Inc. Methods and compositions for treating preterm labor
SE9704644D0 (sv) 1997-12-12 1997-12-12 Astra Ab New use
US6673908B1 (en) 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
BR0013469B1 (pt) 1999-08-20 2011-01-25 amidas aromáticas heterocìclicas fungicidas, composição fungicida compreendendo as mesmas, bem como método para o controle ou a prevenção de infestação fúngica.
US6806314B2 (en) 2003-02-03 2004-10-19 Ppg Industries Ohio, Inc. Coating of Hydroxy-functional polymer(s), crosslinker, and 1,3- and 1,4-cyclohexane dimethanols
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
WO2004089892A2 (en) 2003-04-01 2004-10-21 Theravance, Inc. Diarylmethyl and related compounds having beta2 andrenergic receptor agonist and muscarinic receptor antagonist activity
ATE435862T1 (de) 2003-05-28 2009-07-15 Theravance Inc Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
WO2005080375A1 (en) 2004-02-13 2005-09-01 Theravance, Inc. Crystalline form of a biphenyl compound
DE102004024453A1 (de) 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
WO2006023457A1 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
WO2006023460A2 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
EP1924553A1 (en) 2005-08-08 2008-05-28 Argenta Discovery Limited Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
MX2008011963A (es) 2006-03-20 2008-10-01 Pfizer Ltd Derivados de amina.
GB0613154D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0702384D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd Chemical compounds
WO2008017827A2 (en) 2006-08-08 2008-02-14 Argenta Discovery Limited Azole and thiazole derivatives and their uses
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
BRPI0719270A2 (pt) 2006-10-04 2014-03-11 Pfizer Ltd Derivados de sulfonamida como agonistas adrenérgicos e antagonistas muscarínicos
GB0700972D0 (en) 2007-01-18 2007-02-28 Imp Innovations Ltd Treatment of inflammatory disease
WO2008096129A1 (en) 2007-02-07 2008-08-14 Argenta Discovery Ltd Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
GB0702413D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New chemical compounds
WO2008149110A1 (en) 2007-06-08 2008-12-11 Argenta Discovery Limited Bicyclor [2.2.1] hept-7-ylamine derivatives and their use in the treatment of diseases and conditions in which m3 muscarinic receptor activity and beta-adrenergic activity are implicated
UY31235A1 (es) 2007-07-21 2009-03-02 Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
WO2009017813A1 (en) * 2007-08-02 2009-02-05 Teva Pharmaceutical Industries Ltd. O-desmethyl venlafaxine saccharinate
KR101273200B1 (ko) 2008-02-06 2013-06-17 펄마젠 쎄라퓨틱스 (시너지) 리미티드 화합물
CN101544572B (zh) 2008-03-26 2013-03-20 连云港恒邦医药科技有限公司 一种氨溴索衍生物及其制备方法
GB0808708D0 (en) 2008-05-13 2008-06-18 Astrazeneca Ab New compounds 274
CN102131505A (zh) * 2008-06-20 2011-07-20 阿斯利康(瑞典)有限公司 用于调节β2-肾上腺素受体活性的包含4-羟基-2-氧代-2，3-二氢-1，3-苯并噻唑-7-基化合物的药物组合物
US8263623B2 (en) 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
PT2599778T (pt) 2009-04-23 2017-06-06 Theravance Respiratory Co Llc Compostos de diamida possuindo actividade antagonista do receptor muscarínico e agonista do receptor adrenérgico beta 2
WO2010126025A1 (ja) 2009-04-30 2010-11-04 帝人ファーマ株式会社 四級アンモニウム塩化合物
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
GB201002612D0 (en) * 2010-02-16 2010-03-31 Jagotec Ag Improvements in or relating to organic compounds
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
AR083115A1 (es) 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
HRP20151317T1 (hr) 2011-06-10 2016-01-01 Chiesi Farmaceutici S.P.A. Spojevi koji pokazuju aktivnost prema antagonistima muskarinskog receptora i beta2 adrenergiäśnog receptora
RU2606121C2 (ru) 2011-06-10 2017-01-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Соединения, обладающие антагонистической активностью в отношении мускариновых рецепторов и агонистической активностью в отношении бета2-адренорецепторов
GEP201706656B (en) 2011-11-11 2017-04-25 Pfizer 2-thiopyrimidinones
ES2665580T3 (es) 2011-11-11 2018-04-26 Gilead Apollo, Llc Inhibidores de ACC y usos de los mismos
UA111867C2 (uk) 2011-11-11 2016-06-24 Аллерган, Інк. ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ І СПОСІБ ЗАСТОСУВАННЯ ПОХІДНИХ 4-ПРЕГНЕН-11β-17-21-ТРІОЛ-3,20-ДІОНУ
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592077A1 (en) * 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP3345904B1 (en) 2012-12-06 2020-07-29 Chiesi Farmaceutici S.p.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
KR102156441B1 (ko) 2012-12-06 2020-09-17 키에시 파르마슈티시 엣스. 피. 에이. 무스카린성 수용체 길항제 및 베타2 아드레날린성 수용체 효능제 활성을 가지는 화합물
AU2013360866A1 (en) 2012-12-18 2015-07-02 Almirall, S.A. New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activity
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201440768A (zh) 2013-02-27 2014-11-01 Almirall Sa 雙毒蕈鹼拮抗劑-β2腎上腺素促效劑複合物及皮質類固醇之組合物
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物

Also Published As

Publication number Publication date
PH12016500125B1 (en) 2016-04-25
LT3024489T (lt) 2020-03-10
BR112016001295A2 (es) 2017-07-25
WO2015011244A1 (en) 2015-01-29
ES2788627T3 (es) 2020-10-22
UY35678A (es) 2015-02-27
TWI641373B (zh) 2018-11-21
AU2014295028B2 (en) 2018-05-31
SI3024489T1 (sl) 2020-04-30
MY184681A (en) 2021-04-16
US20160166566A1 (en) 2016-06-16
DOP2016000011A (es) 2016-06-15
IL243173B (en) 2019-10-31
ZA201509203B (en) 2017-04-26
MX360837B (es) 2018-11-20
NZ715128A (en) 2019-03-29
IL243173A0 (en) 2016-02-29
PL3024489T3 (pl) 2020-08-10
DK3024489T3 (da) 2020-05-04
CA2917596C (en) 2021-06-22
MX2016000397A (es) 2016-04-29
KR102338155B1 (ko) 2021-12-10
TW201517907A (zh) 2015-05-16
HK1219043A1 (en) 2017-03-24
HRP20200670T1 (hr) 2020-07-10
RS60185B1 (sr) 2020-06-30
BR112016001295B1 (pt) 2022-07-19
CA2917596A1 (en) 2015-01-29
PT3024489T (pt) 2020-05-05
PH12016500125A1 (en) 2016-04-25
NI201600012A (es) 2016-10-10
CR20160043A (es) 2016-04-08
AU2014295028A1 (en) 2016-01-21
SG11201510682YA (en) 2016-02-26
CN105492027A (zh) 2016-04-13
JP6374962B2 (ja) 2018-08-15
PE20160173A1 (es) 2016-04-13
EP3024489B1 (en) 2020-02-19
KR20160034310A (ko) 2016-03-29
EP3024489A1 (en) 2016-06-01
EA035436B1 (ru) 2020-06-15
EA201600128A1 (ru) 2016-07-29
JP2016525533A (ja) 2016-08-25
SMT202000185T1 (it) 2020-05-08
HUE049441T2 (hu) 2020-09-28
CN112321579A (zh) 2021-02-05
AR097079A1 (es) 2016-02-17
US9579316B2 (en) 2017-02-28
CY1122920T1 (el) 2021-10-29

Similar Documents

Publication Publication Date Title
CY1123476T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
UY35355A (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONIS TA DEL RECEPTOR ß2 ADRENÉRGICO ASÍ COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARÍNICO M3.
DOP2016000011A (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD ANTAGONISTA DE RECEPTORES MUSCARÍNICOS ASÍ COMO ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENÉRGICO
NI201400108A (es) Compuestos de heterociclilo
CO6680717A2 (es) Derivados de quinolina y quinoxalina como inhibidores de cinasa
CR20140076A (es) 4-(8-metoxipropan-2-il)-2-(tetrahidro-2h-piran-4-il)-1h-imidazo [4,5-c] quinolin-7-il)-3,5-dimetilisoxazol y su uso como inhibidor de bromodominio
CL2013002650A1 (es) Compuestos derivados triciclicos con actividad sobre los receptores hormonales nucleares; composicion farmaceutica que los comprende; proceso de reparacion de compuestos intermediarios; y uso en el tratamiento del sida, insuficiencia adrenal aguda, enfermedad de addison, rinitis alergica, enfermedad de alzheimer, entre otros.
CL2015000121A1 (es) El compuesto 1-(1-metil-1h-pirazol-4-il)-n-((1r,5s,7s)-9-metil-3-oxa-9-azabiciclo[3.3.1]-nonan-7-il)-1h-indol-3-carboxamida, antagonista del receptor de 5-ht3; composicion farmaceutica; y su uso como medicamento
PE20151414A1 (es) NUEVOS DERIVADOS CARBAMATO DE CICLOHEXILO Y QUINUCLIDINILO QUE TIENEN ACTIVIDAD COMO AGONISTAS ß2 ADRENERGICOS Y COMO ANTAGONISTAS MUSCARINICOS M3
CR20140182A (es) Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenérgicos b2 y como antagonistas muscarínicos m3
GT201200307A (es) NUEVOS DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENÉRGICOS ß2 Y COMO ANTAGONISTAS MUSCARÍNICOS M3
CR20140181A (es) Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenérgicos b2 y como antagonistas muscarínicos m3
MX381819B (es) Derivados de heterociclico opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas oncológicas y autoinmunitarias.
CR20140516A (es) Compuestos de pirazol sustituidos como antagonistas de lpar
UY35708A (es) Compuestos novedosos como antagonistas del receptor de ácido lisofosfatidico
ECSP14002542A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
MX2015013328A (es) Uso de antagonistas del receptor de ep4 en el tratamiento de enfermedad de cartilago.
UY36329A (es) NUEVOS DERIVADOS BICÍCLICOS QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENÉRGICOS ß2 Y COMO ANTAGONISTAS MUSCARÍNICOS M3
GT201300304A (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
BR112016005361A8 (pt) inibidores de girase tricíclica, composição, forma de dosagem, embalagem e dispositivo dispensador que os compreende, bem como uso dos mesmos
MX378175B (es) Novedosos compuestos heterocíclicos y su uso tanto en medicina como en cosmética.
NI201500107A (es) Sales de derivados de 2-amino-1-hidroxietil-8-hidroxiquinolin-2(1h)-ona que tienen actividad agonista del receptor b2 adrenérgico así como actividad antagonista del receptor muscarínico m3.
UA112586C2 (uk) Похідні бензімідазолпроліну